Valvular & structural heart disease
Multimarker Approach to Improve Risk Stratification of Patients Undergoing Transcatheter Aortic Valve Implantation
Authors' conclusion
An increasing number of elevated blood biomarkers is associated with higher risks of adverse clinical outcomes following TAVI.
Study context
- Population
- Patients undergoing transcatheter aortic valve implantation (TAVI)
- Participants
- 362 patients
- Exposure
- Number of elevated blood biomarkers
- Outcome
- All-cause mortality
- Follow-up
- Median 2.5 (IQR: 1.9-3.2) years
Main finding
As reported in the abstract
Each group vs 0 to 3 elevated biomarkersHazard ratio (95% CI)P value
4 to 7 elevated biomarkers
1.54(0.84–2.80)
P = 0.168 to 9 elevated biomarkers
2.81(1.53–5.15)
P < 0.001- Died (whole cohort)
- 99 (27%)
- Adding number of elevated biomarkers to clinical multivariable model: Net Reclassification Index
- 0.71, P < 0.001
Observational data: associations, not effects.
Further findings
| Outcome | HR (95% CI) | P value | |
|---|---|---|---|
| Composite of all-cause mortality or HF rehospitalization4 to 7 elevated biomarkersvs 0 to 3 elevated biomarkers | 1.65 (0.95–2.84) | P = 0.07 | |
| Composite of all-cause mortality or HF rehospitalization8 to 9 elevated biomarkersvs 0 to 3 elevated biomarkers | 2.67 (1.52–4.70) | P < 0.001 | |
| 0.20.5125Hazard ratio (log scale) |
- Composite of all-cause mortality or HF rehospitalization — Met composite endpoint (whole cohort)
- 113 (31.2%)
HF rehospitalization (whole cohort)
- Rehospitalized for HF
- 34 (9.4%)
Original publication
Multimarker Approach to Improve Risk Stratification of Patients Undergoing Transcatheter Aortic Valve Implantation. JACC Adv. Published 19 December 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →